ECONOMIC BURDEN OF BURN INJURIES TREATED WITH AN ENZYMATIC DEBRIDING AGENT IN SPAIN
Author(s)
Sanz-Granda Á1, Martínez-Méndez JR2, González-Miranda Á2, Ojeda-Regidor Á2, Casado-Pérez C2
1Proyectos de Farmacoeconomía, Las Rozas de Madrid, Spain, 2University Hospital La Paz, Madrid, Spain
OBJECTIVES: Burn care is considered expensive care by the payers; so, the objective is to analyze the direct cost of burn care in patients treated with a novel enzymatic (bromelain) debriding agent (Nexobrid, NXB) in a reference hospital in Spain and to identify the cost determinants METHODS: Resource use of all patients with deep burns, treated from Dec 2014 to Dec 2016, was analyzed retrospectively from the hospital perspective, until 3 months post injury. Only direct costs were included. Subgroups analyses were carried out to examine differences between them (age, sex, percentage total body surface area (TBSA) burned, type of burn). RESULTS: Average patient (age: 45.8 years and TBSA: 10%) showed an estimated mean cost of €25,697 (n: 75; median: €11,932 €; interquartile range: €5,607 – €32,879 €). The most important cost determinants were ICU stay (€10,615) and hospital stay (€8,104); pharmacologic cost (NXB) was only €2,740. Subgroups analysis showed that total cost was determined by age, TBSA and deep of burn. Cost was lower when age ≤60 (78.7%) than >60: 20,407 € vs. 45,202 €; or if TBSA ≥10% (33.3%) than <10%: €57,245 vs €9,923; or depth of burn (second degree (82.7%): €17,904 vs. third degree: €62,865). Cost was higher in women (25.3%): €31.721 € vs. 23.653 €. CONCLUSIONS: ≥10% showed a higher cost than the average
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PSS14
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Sensory System Disorders
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now